IL37 and psoriasis: Biologics specifically targeting and inhibiting the IL-23/IL-17 axis, such as secukinumab (IL-17A inhibitor) and ustekinumab (IL-12p40 inhibitor) have recently emerged as a new therapeutic strategy for psoriasis and other IL-17/IL-23 driven IMIDs, showing substantial clinical efficacy and safety profiles [10].